AA
FLGT icon

ALPS Advisors’s Fulgent Genetics FLGT Stock Holding History

ALPS Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
25,422
+36
+0.1% +$781 ﹤0.01% 950
2025
Q4 		$667K Buy
25,386
+10,847
+75% +$281K ﹤0.01% 663
2025
Q3 		$329K Sell
14,539
-1,873
-11% -$38.6K ﹤0.01% 946
2025
Q2 		$326K Sell
16,412
-6,340
-28% -$124K ﹤0.01% 907
2025
Q1 		$385K Sell
22,752
-1,980
-8% -$33.7K ﹤0.01% 634
2024
Q4 		$457K Buy
24,732
+1,790
+8% +$34.9K ﹤0.01% 635
2024
Q3 		$499K Sell
22,942
-420
-2% -$9.39K ﹤0.01% 610
2024
Q2 		$458K Buy
+23,362
New +$488K ﹤0.01% 593
2022
Q1 		– Sell
-4,253
Closed -$428K – 879
2021
Q4 		$428K Buy
4,253
+51
+1% +$4.48K ﹤0.01% 593
2021
Q3 		$378K Buy
4,202
+1,101
+36% +$100K ﹤0.01% 622
2021
Q2 		$286K Hold
3,101
– – ﹤0.01% 860
2021
Q1 		$300K Buy
+3,101
New +$320K ﹤0.01% 822

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ALPS Advisors's FLGT Position: Q1 2026 in Review

ALPS Advisors increased its Fulgent Genetics (FLGT) stake by 0.14% in Q1 2026, buying an estimated $781 and bringing the position to 25,422 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #950.

ALPS Advisors first reported a position in FLGT in Q1 2021 and has held it in 12 quarters since. The position peaked at $667K in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • ALPS Advisors held 25,422 shares of Fulgent Genetics worth $404K as of Q1 2026.
  • ALPS Advisors bought 36 Fulgent Genetics shares in Q1 2026, an estimated $781.
  • Fulgent Genetics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #950 holding.
  • ALPS Advisors first reported a position in Fulgent Genetics in Q1 2021 and has held it in 12 quarters since.
  • ALPS Advisors's Fulgent Genetics position peaked at $667K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.